Revance

Revance Therapeutics, Inc. is a biotechnology company specializing in innovative aesthetic and therapeutic solutions. Their flagship product, DAXXIFY® (daxibotulinumtoxinA-lanm), is a next-generation neuromodulator designed to temporarily improve the appearance of moderate to severe glabellar lines, commonly known as frown lines.

DAXXIFY® utilizes a proprietary peptide-powered technology, offering a longer-lasting effect compared to traditional botulinum toxin products.

In addition to DAXXIFY®, Revance offers a comprehensive portfolio of aesthetic and skincare products. This includes the RHA® Collection of dermal fillers, the first and only FDA-approved range for correcting dynamic facial wrinkles and folds.

They also provide the HintMD fintech platform, which integrates smart payment, subscription, and loyalty digital services tailored for U.S. aesthetic practices.

Therapeutic Applications

Therapeutically, Revance is advancing DAXXIFY® for the treatment of cervical dystonia, a neurological disorder characterized by muscle contractions.

They are also exploring its potential in treating adult upper limb spasticity, a condition involving muscle stiffness.

Company Acquisition

In August 2024, Revance was acquired by Crown Laboratories, Inc. for $924 million, aiming to enhance their competitive position in the aesthetic products market.

Locations

Revance operates globally, with a presence in over 60 countries.

In the United States, the company has offices in several key locations including:

• Atlanta, GA, USA
• St. Louis, MO, USA
• Nashville, Tennessee
• Fremont, California
• Newark, California